Citation:Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al 2000

From Cancer Guidelines Wiki

Citation


Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000 Jun;18(12):2354-62 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10856094.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?